{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:18:35Z","timestamp":1772497115742,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clim.2023.109247","type":"journal-article","created":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T14:56:07Z","timestamp":1675004167000},"page":"109247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Consecutive injections of low-dose interleukin-2 improve symptoms and disease control in patients with chronic spontaneous urticaria"],"prefix":"10.1016","volume":"247","author":[{"given":"Jiaqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liting","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanyu","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwen","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianjin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2023.109247_bb0005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.clim.2023.109247_bb0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.clim.2023.109247_bb0015","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/CM9.0000000000002172","article-title":"Epidemiology of urticaria in China: a population-based study","volume":"135","author":"Li","year":"2022","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.clim.2023.109247_bb0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2500\/aap.2018.39.4121","article-title":"Diagnosis, pathogenesis, and treatment of chronic spontaneous urticaria","volume":"39","author":"Kaplan","year":"2018","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.clim.2023.109247_bb0025","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaip.2020.11.043","article-title":"Biologics for the use in chronic spontaneous urticaria: when and which","volume":"9","author":"Maurer","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clim.2023.109247_bb0030","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3389\/fimmu.2019.00627","article-title":"Autoimmune theories of chronic spontaneous Urticaria","volume":"10","author":"Bracken","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2023.109247_bb0035","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109247_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.08.050","article-title":"Autoimmune chronic spontaneous urticaria: What we know and what we do not know","volume":"139","author":"Kolkhir","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109247_bb0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12016-021-08886-x","article-title":"Chronic Urticaria: advances in understanding of the disease and clinical management","volume":"61","author":"He","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.clim.2023.109247_bb0050","doi-asserted-by":"crossref","first-page":"545","DOI":"10.4168\/aair.2021.13.4.545","article-title":"Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous Urticaria","volume":"13","author":"Kolkhir","year":"2021","journal-title":"Allergy, Asthma Immunol. Res."},{"key":"10.1016\/j.clim.2023.109247_bb0055","article-title":"Genome-wide association study of chronic spontaneous urticaria reveals genetic overlap with autoimmune diseases, not atopic diseases","author":"Zhang","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2023.109247_bb0060","doi-asserted-by":"crossref","first-page":"e561","DOI":"10.1111\/ijd.12630","article-title":"Circulating level of CD4+ CD25+ FOXP3+ T cells in patients with chronic urticaria","volume":"53","author":"Arshi","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.clim.2023.109247_bb0065","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1111\/j.1440-0960.2010.00658.x","article-title":"Detection of CD4+ CD25+ FOXP3+ regulatory T cells in peripheral blood of patients with chronic autoimmune urticaria","volume":"52","author":"Sun","year":"2011","journal-title":"Austral. J. Dermatol."},{"key":"10.1016\/j.clim.2023.109247_bb0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jdermsci.2008.02.012","article-title":"Defective functions of circulating CD4+CD25+ and CD4+CD25- T cells in patients with chronic ordinary urticaria","volume":"51","author":"Chen","year":"2008","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.clim.2023.109247_bb0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11926-020-00978-5","article-title":"T cell abnormalities in the pathogenesis of systemic lupus erythematosus: an update","volume":"23","author":"Chen","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2023.109247_bb0080","first-page":"S73","article-title":"Interleukin-2-based therapy for metastatic renal cell cancer: the cytokine working group experience, 1989-1997","volume":"3","author":"Dutcher","year":"1997","journal-title":"Cancer J. Sci. Am."},{"key":"10.1016\/j.clim.2023.109247_bb0085","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2023.109247_bb0090","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109247_bb0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2023.109247_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.08.015","article-title":"Low-Dose IL-2 for treating moderate to severe Alopecia Areata: a 52-week multicenter prospective placebo-controlled study assessing its impact on T regulatory cell and NK cell populations","volume":"141","author":"Le Duff","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2023.109247_bb0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clim.2023.109247_bb0110","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00125-020-05200-w","article-title":"Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a phase I\/II randomised, double-blind, placebo-controlled, dose-finding study","volume":"63","author":"Rosenzwajg","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.clim.2023.109247_bb0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2023.109247_bb0120","doi-asserted-by":"crossref","first-page":"102906","DOI":"10.1016\/j.autrev.2021.102906","article-title":"Low-dose interleukin-2: a potential treatment for pemphigus vulgaris","volume":"20","author":"Long","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2023.109247_bb0125","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.clim.2023.109247_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109247_bb0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2023.109247_bb0140","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","article-title":"Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial","volume":"27","author":"Metz","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109247_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.04.036","article-title":"Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor I\u03b1 subunit","volume":"138","author":"Auyeung","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109247_bb0150","first-page":"4434","article-title":"Pathogenic role of circulating CD4(+)CXCR5(+) cell subpopulations in patients with chronic spontaneous urticarial","volume":"12","author":"Gao","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.clim.2023.109247_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/science.aao2933","article-title":"Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helper T cells","volume":"361","author":"DiToro","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.clim.2023.109247_bb0160","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/art.41457","article-title":"Conversion of T follicular helper cells to T follicular regulatory cells by Interleukin-2 through transcriptional regulation in systemic lupus erythematosus","volume":"73","author":"Hao","year":"2021","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2023.109247_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.09.003","article-title":"Demonstration and implications of IL-3 upregulation of CD25 expression on human mast cells","volume":"149","author":"Yin","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109247_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109247_bb0175","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1398-9995.2009.02132.x","article-title":"EAACI\/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria","volume":"64","author":"Konstantinou","year":"2009","journal-title":"Allergy"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623000268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623000268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T04:06:40Z","timestamp":1738901200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661623000268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":35,"alternative-id":["S1521661623000268"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2023.109247","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consecutive injections of low-dose interleukin-2 improve symptoms and disease control in patients with chronic spontaneous urticaria","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2023.109247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109247"}}